Clinical Trial Update: Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating irinotecan and docetaxel for metastatic or locally recurrent head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED